Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2145)

[mfierke]

Antwort auf Beitrag Nr.: 64.166.476 von nicolani am 24.06.20 20:50:29

dass sie die 2.welle noch rollen lassen!

davon bin ich auch überzeugt

[nicolani]

das war kein mut, war nur der glaube in diese drecksbrut! donald rumsfeld und co. schau mal ein wenig vorher hatte ich hierzu stellung bezogen! für mich jetzt free-ride, aber irgendwo ist dann auch mal meine vorstellung am ende angekommen! corona ist für mich eh nur ein fake, wobei wir meiner frühen einschätzung immer näher kommen! wobei ich glaube, dass sie die 2.welle noch rollen lassen!

[mfierke]

Antwort auf Beitrag Nr.: 64.165.561 von nicolani am 24.06.20 19:45:07

Glückwunsch für Deinen Mut. ich schaue schon Tage zu. Jetzt noch reingehen, dafür fehlt mir Etwas.
Bin sehr gut in Biotech investiert. aber jeden Tag mehr Verluste.
ich bleibe Euch als Zuschauer treu. einen schönen Abend und weiterhin gute Gewinne

[nicolani]

hier wo die post abgeht, ist wohl niemand mehr drin! leider auch ich nach tenbagger 80% rausgegeben! aber jetzt wo zacks von 2.welle-aktie spricht, bleibe ich noch eine weile!

[Magnetfeldfredy]

Novavax price target raised to $88 from $45 at Cantor Fitzgerald 07:01 NVAX Cantor Fitzgerald analyst Charles Duncan raised the firm's price target on Novavax to $88 from $45 and reiterates an Overweight rating on the shares. The stock closed Thursday up $3.86 to $59.27. The recent additions of "well-known and established biotech veterans" to Novavax's executive team are "value-creating" due to experience and "fresh thinking," Duncan tells investors in a research note. The analyst sees Filip Dubovsky being named Chief Medical Officer and Silvia Taylor named SVP, Investor Relations and Corporate Affairs as external validation of Novavax's maturing pipeline and potential broad applicability of its platform recombinant nanoparticle/Matrix-M adjuvant platforms. Duncan now has increased conviction in Novavax's pipeline potential.

Read more at:
https://thefly.com/landingPageNews.php?id=3113285

[mfierke]

Antwort auf Beitrag Nr.: 64.021.953 von DasTier666 am 15.06.20 16:40:31

hier schreiben wirklich wenige, dabei läuft sie so gut

[DasTier666]

Novavax to Raise $200 Million from Private Placement with RA Capital
GlobeNewswireJune 15, 2020

Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has entered into an agreement to sell Series A Convertible preferred stock, convertible into 4,388,852 shares of common stock, to an investment fund affiliated with RA Capital Management (RA Capital) in a private placement, at an effective purchase price per share of common stock equal to the June 12, 2020 closing price. Upon closing Novavax will receive gross proceeds of approximately $200 million.

“We are extremely pleased to receive this tremendous support from RA Capital, which we believe signals a high level of confidence in the significant progress of our COVID-19 and influenza vaccine programs,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “This additional infusion of capital supplements our strong cash position and the significant funding from CEPI and the U.S. Department of Defense, providing us with the capacity to execute on our critical priority of providing a vaccine against the COVID-19 pandemic as quickly as possible, and to progress NanoFlu to BLA filing.”
...

https://finance.yahoo.com/news/novavax-raise-200-million-pri…

[hn068]

https://finance-yahoo-com.cdn.ampproject.org/v/s/finance.yah…

[Magnetfeldfredy]

Blöder Trump:


Novavax gets U.S. defense funding for its COVID-19 vaccine
[Reuters]
Reuters•June 5, 2020

June 4 (Reuters) - Novavax Inc said on Thursday the U.S. Department of Defense (DoD) will give the late-stage biotech company up to $60 million to fund the manufacturing of its experimental COVID-19 vaccine. The U.S.-based company said the deal includes the delivery of 10 million doses of its COVID-19 vaccine - NVX-CoV2373 - to the DoD this year.

The announcement of Novavax's vaccine trial came last month as drugmakers pause clinical trials on drugs for other ailments to focus on COVID-19, the illness caused by the novel coronavirus that has resulted in more than 386,379 deaths globally.

The Maryland-based company joined the race to test coronavirus vaccine candidates on humans and said it was targeting the production of over a billion doses of its vaccine candidate next year.

Preliminary data from its first participants on safety and indicators of an immune response from the trial is expected next month.

Vaccines are seen by world leaders as the only real way to restart their stalled economies after months of sweeping shutdowns. (Reporting by Sanjana Shivdas in Bengaluru, Editing by Sherry Jacob-Phillips)

[Magnetfeldfredy]

Why Didn't Novavax Make Trump's Top 5 COVID-19 Vaccine List?
Novavax is well ahead in clinical testing than two of the White House's COVID-19 vaccine finalists.
Keith Speights
Keith Speights
(TMFFishBiz)
Jun 4, 2020 at 8:23AM
Author Bio

No company has developed a COVID-19 vaccine that's been proven to be safe and effective yet. But several appear to be getting a big boost for their efforts from Uncle Sam.

The New York Times reported on Wednesday that the Trump administration has selected five finalists among the companies developing COVID-19 vaccine candidates. Each of these drugmakers will receive federal money plus assistance in their clinical studies and manufacturing efforts.

There's a reasonable case to be made for the U.S. government to help the companies with the most promising COVID-19 vaccine candidates. But I think the reported list raised a big question: Why wasn't Novavax (NASDAQ:NVAX) in the top five?
President Trump at a podium

Image source: WhiteHouse.gov.
White House favorites

Which drugmakers did make the Trump administration's list of finalists? To no one's surprise, Moderna (NASDAQ:MRNA) was in the group. The biotech's COVID-19 vaccine candidate, mRNA-1273, is already in a phase 2 clinical study. Moderna reported encouraging initial results from its phase 1 study of the vaccine last month.

Another obvious contender is the partnership between AstraZeneca (NYSE:AZN) and the University of Oxford. Like Moderna, the AstraZeneca-Oxford team is currently evaluating COVID-19 vaccine candidate AZD1222 in a phase 2 clinical study.

It also makes sense to me that Pfizer (NYSE:PFE) made the cut. Pfizer is working with German biotech BioNTech (NASDAQ:BNTX) to develop messenger RNA COVID-19 vaccine BNT162. The vaccine is in phase 1 clinical trials in the U.S. and Germany.

Two companies that haven't advanced COVID-19 vaccine candidates to clinical testing yet were also included in the White House favorites. Johnson & Johnson (NYSE:JNJ) selected a candidate in March and plans to begin early stage clinical testing in September. Merck (NYSE:MRK) only recently jumped into the COVID-19 vaccine race, announcing on May 26 that it will acquire Themis, a small company that's developing a COVID-19 vaccine, and partner with nonprofit organization IAVI to develop another COVID-19 vaccine.
Two COVID-19 vaccine bottles standing with two toppled over

Image source: Getty Images.
The argument for Novavax

I think there's a strong case to be made that Novavax deserved to be on the Trump administration's list of finalists. Importantly, the biotech is ahead of both J&J and Merck. Novavax began its phase 1/2 clinical trial of COVID-19 vaccine candidate NVX‑CoV2373 late last month.

It seems likely that Novavax will advance NVX-CoV2373 into phase 2 testing before J&J and Merck crank up phase 1 clinical trials of their respective COVID-19 vaccine candidates. That's a pretty big head start that on the surface appears to have been overlooked by the White House.

What's more, Novavax's COVID-19 vaccine candidate is clearly promising. Last month, the Coalition for Epidemic Preparedness Innovations (CEPI) awarded its biggest grant to date for a COVID-19 vaccine, committing to provide up to $388 million in funding to Novavax for its COVID-19 vaccine efforts.

CEPI's endorsement is a big deal. The organization was founded by the Bill and Melinda Gates Foundation, U.K.-based research charity the Wellcome Trust, the World Economic Forum, and the governments of Norway and India. It has also received financial support from the governments of Australia, Belgium, Canada, Denmark, Ethiopia, Germany, Japan, Mexico, Norway, and the U.K.

In addition, Novavax should be in a good position to scale up the production of its vaccine thanks to the CEPI funding. The biotech announced on May 27 that it's acquiring Praha Vaccines in a deal that will enable it to produce over 1 billion doses per year of its vaccine beginning in 2021.

Sure, Novavax is still a clinical-stage biotech. But so is Moderna. And unlike Moderna, Novavax has already reported successful phase 3 results for another vaccine based on its nanoparticle technology -- flu vaccine NanoFlu.
Will it matter?

Some might argue that politics played a role in the companies selected by the White House. Three of the companies making the cut were invited to meet with President Trump in March. U.K.-based AstraZeneca and Merck were the two exceptions. All of them but Moderna are big pharmaceutical companies. And Moderna has been joined at the hip with the National Institutes of Health since early this year.

It's likely that we'll never know for sure why Novavax didn't make the Trump administration's list of finalists and Merck, a late-comer to the COVID-19 vaccine scene, did. But will it really matter over the long run? Probably not.

Novavax's CEPI funding should enable the company to advance NVX-CoV2373 through late-stage clinical studies, assuming all goes well with earlier clinical trials. In the end, the COVID-19 vaccines that prove to be the safest and most effective in clinical testing will be the real winners. And those winners may or may not be the ones that the White House handpicked.